Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Biagio Campo is active.

Publication


Featured researches published by Biagio Campo.


European Urology | 2000

AMS Three–Piece Inflatable Implants for Erectile Dysfunction: A Long–Term Multi–Institutional Study in 200 Consecutive Patients

Francesco Montorsi; Patrizio Rigatti; Giorgio Carmignani; Carlo Corbu; Biagio Campo; Giorgio Ordesi; G. Breda; Pasquale Silvestre; Bruno Giammusso; Giuseppe Morgia; Alessandra Graziottin

Objectives: The aim of this study was to assess the longterm mechanical reliability of AMS (American Medical Systems) three–piece inflatable implants and their impact on patient–partner satisfaction in 200 consecutive patients with erectile dysfunction who underwent surgery in five different institutions.Methods: Patient charts included in the study were collected and extensively assessed to record pre– and intraoperative data and postoperative complications. All patients and 120 partners were then seen often in the office at a mean follow–up of 59 months (range 6–130) and they were extensively questioned about function of the device and its impact on the couple’s sexual life.Results: At the long–term follow–up, 185 patients (92.5%) were still engaging in sexual intercourse with a mean frequency of 1.7/week. Patients and partners reported prosthetic erections as excellent, satisfactory or poor in 96 (48%), 100 (50%) and 4 (2%) cases, and in 20 (17%), 80 (66%) and 20 (17%) cases, respectively. Postoperative sexual activity was considered excellent, satisfactory or poor by 140 (70%), 44 (22%) and 16 (8%) patients and by 34 (28%), 81 (68%) and 5 (4%) partners, respectively. Reasons for patients’ complaints included postoperative penile shortening in 60 (30%) cases and poor glandular engorgement in 40 (20%) cases. Partners’ main complaint was unnaturalness of the prosthetic erection, a factor reported by 30 (25%) subjects. Complications requiring surgical exploration included infection in 12 patients (6%) and mechanical failure in 8 patients (4%). Kaplan–Meier estimates demonstrated significantly decreased mechanical survival for the Ultrex type of cylinders compared to the CX type of cylinders.Conclusions: AMS three–piece inflatable implants provide an overall patient and partner satisfaction rate of 92 and 96%, respectively. However, postoperative penile shortening and poor glandular engorgement were the causes of some complaints among the patient population as well as the unnaturalness of prosthetic erection among female partners. In the long–term, mechanically speaking, CX cylinders seem to be more reliable than the Ultrex ones.


Urology | 1997

Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation

Biagio Campo; Franco Bergamaschi; Piero Corrada; Giorgio Ordesi

OBJECTIVES This prospective study evaluated the clinical and urodynamic changes in patients with obstruction due to benign prostatic hyperplasia (BPH) treated with transurethral needle ablation (TUNA). METHODS One hundred twenty patients with obstructive uropathy due to BPH were treated with the TUNA procedure between January 1994 and December 1995. All patients were selected according to the criteria established by the guidelines proposed by the International Consensus Committee (World Health Organization, Paris, 1993). The TUNA procedure was performed in an outpatient setting using topical intraurethral anesthesia (2% lidocaine gel). RESULTS Patients showed a decrease in irritative symptoms as measured by the international Prostate Symptom Score (IPSS) and postprocedure urodynamic parameters. The mean (+/- SD) pretreatment IPSS was 20.8 +/- 4.5. At 3 months, the IPSS decreased to 9.7 +/- 3.0 (108 patients) (P < 0.001). At 6 months it decreased to 6.8 +/- 3.1 (86 patients) and remained at 6.2 +/- 2.9 (72 patients) and 6.7 +/- 3.8 (42 patients) at 12 and 18 months, respectively (P < 0.001). At 1 year after treatment, the peak flow rate (Qmax) increased from 8.2 +/- 3.4 mL/s to 15.9 +/- 2.1 mL/s and was 14.1 +/- 2.5 mL/s at 18 months of follow-up (P < 0.01). Urodynamic re-evaluation performed in 72 patients 12 months after TUNA demonstrated the absence of obstruction in 30 (41.7%). An additional 30 patients (41.7%) had equivocal results, whereas the remaining 12 (16.6%) still had obstruction, according to the Abrams-Griffith nomogram. Mean detrusor pressure at Qmax decreased from 85.3 +/- 18.5 cm H2O to 63.7 +/- 24.9 cm H2O at 12 months of follow-up. CONCLUSIONS Our results confirm that the TUNA procedure is safe and effective when performed as an outpatient procedure. In addition, TUNA produced better results in patients presenting with moderate to severe irritative symptoms and minimal obstruction as determined by pressure/flow studies.


The Journal of Urology | 1991

Systemic preoperative chemotherapy with cisplatin, methotrexate and vinblastine for locally advanced bladder cancer: Local tumor response and early followup results

Massimo Maffezzini; Tullio Torelli; Eugenio Villa; Paolo Corrada; Angelo Bolognesi; Gianni Lorenzo Leidi; Patrizio Rigatti; Biagio Campo

A total of 44 patients with infiltrating, locally advanced bladder cancer (stages T 3a-b, T 4a-b and N+/N0) were treated with the systemic chemotherapy regimen of cisplatin, methotrexate and vinblastine (CMV) in the neoadjuvant setting, of whom 39 were evaluable for response. After planned radical cystectomy and 2 to 3 cycles of chemotherapy no tumor was found on the pathological specimen of 4 patients (10%), the tumor was downstaged in 19 (49%) and no change was observed in 16 (41%). Toxicity included leukopenia in 29 patients (66%), 1 of whom died of granulocytopenic sepsis, nausea and vomiting in 39 (89%) and mild to moderate mucositis in 18 (41%). Median followup is 12 months with a range of 6 to 39 months. Of 32 patients followed for longer than 6 months 6 (19%) experienced progression or recurrence of disease. We conclude that preoperative CMV chemotherapy is effective in inducing downstaging of the tumor, although systemic toxicity limits its use to cautiously selected patients.


International Journal of Surgical Pathology | 2009

Cell Discohesion and Multifocality of Carcinoma In situ of the Bladder: New Insight From the Adhesion Molecule Profile (e-Cadherin, Ep-CAM, and MUC1)

Carlo Patriarca; Piergiuseppe Colombo; Angelo Taronna; Jelle Wesseling; Giada Franchi; Francesca Guddo; Richard Naspro; Roberto Maria Macchi; Paolo Giunta; Marcello Di Pasquale; Michele Parente; Carmelo Arizzi; Massimo Roncalli; Biagio Campo

Urothelial cell carcinoma in situ (CIS) of the bladder is a superficially diffusive and highly discohesive disease. The authors analyzed the expression of some adhesion molecules (e-cadherin and Ep-CAM) and MUC1 in 32 unifocal and multifocal bladder urothelial cell CIS in an attempt to clarify this discohesion. E-cadherin was strongly expressed, in more than 75% of the cases. The presence of methylation of the CDH1 e-cadherin promoter gene was also investigated, but methylation was found in only one case. Ep-CAM was present in all the cases with a heterogeneous staining pattern. Similarly, MUC1/episialin was variously present in 94% of the cases without a polarized staining pattern and was expressed more strongly in cases with multifocal disease. Because loss of MUC1 polarization leads to interference with cell—cell adhesion mechanisms mediated by cadherins, these findings help explain why bladder urothelial cell CIS often shows a discohesive morphology and multifocality despite a strongly expressed adhesion molecule profile. Finally, Ep-CAM expression might provide some support for future target therapy trials.


Tumori | 1984

Bladder urethral dysfunction after abdominoperineal resection of the rectum for ano-rectal cancer.

Rita Zanolla; Biagio Campo; Giorgio Ordesi; Gemma Martino

We prospectively studied bladder and urethral function in 44 patients before and after abdominoperineal resection of the rectum for anorectal cancer. The patients were investigated with the following examinations: combined cystometry and electromyography, urethral pressure profile measurement, urecholine denervation test, urine culture, urethrogram and residual urine measurement after voiding. Urodynamic results after surgery demonstrated the partial or total denervation of the detrusor muscle with bladder areflexia in the 54 % of the cases, the decrease in the urethral pressure profile in the 48 % of the cases, and the absence of detrusor sphincter dyssynergia in all cases. Urethrogram results showed a high incidence of bladder dislocation into the presacral space (36 %). Urine cultures were frequently positive in 52 % of the patients. Most patients (52 %) had difficulty in voiding with high residual urine and/or stress incontinence (4.5 %). All the patients received an early rehabilitative treatment with kinesitherapy and/or pharmacologic therapy after bladder catheter removal and after urodynamic results. The patients with neurogenic bladder with residual urine volume had satisfactory functional recovery of the activity.


Prostate Cancer and Prostatic Diseases | 2006

Histopathological findings after radiofrequency (RITA) treatment for prostate cancer

Carlo Patriarca; F Bergamaschi; G Gazzano; P Corrada; G Ordesi; L Zanitzer; M Di Pasquale; Paolo Giunta; Biagio Campo

Radiofrequency interstitial tumor ablation (RITA) is a thermal ablation method that uses needles and low radiofrequency (RF) energy. The aim of our study was to evaluate the histopathology of thermal lesions induced by RF energy delivered interstitially in prostate cancer patients who subsequently underwent prostatectomy, and to determine the feasibility, effectiveness and safety of this new method in a pilot study.


Tumori | 1996

Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: The impact of pathologic response on long-term results

Vincenzo Scattoni; Angelo Bolognesi; C. Cozzarini; Francesco Francesca; Marco Grasso; Laura Galli; Tullio Torelli; Biagio Campo; Eugenic Villa; Patrizio Rigatti

Aims and Background Neoadjuvant systemic chemotherapy in infiltrating transitional cell carcinoma of the bladder has proved to be effective and to provide a pathologic complete response in about 30% of patients. No survival benefit has yet been proved. Methods We analyzed the outcome of 75 patients with advanced bladder cancer (stages T2-T4 N+/N0 M0) treated from 1985 to 1993 at two institutions in the same geographic area with 2 or 3 cycles of neoadjuvant CMV (cisplatin, methotrexate and vinblastine) chemotherapy plus cystectomy. Transurethral resection of the tumor was expressly avoided in order to keep the tumor intact as a marker lesion to evaluate response to chemotherapy. Results At the time of analysis, the median follow-up of 67 assessable patients was 51.5±3.9 (SE) months. Forty-six patients (69%) had clinical evidence of extravesical spread of the bladder tumor and 6 of lymph node metastases at presentation. After cystectomy, a pathologic complete response (pT0, pN0) was achieved in only 6 cases (9%) and a pathologic partial response in 32 patients (48%). The overall 5-year survival rate of all patients was 61 ±6%. Those patients who had a major response to chemotherapy (pCR + pPR) had a 5-year disease-free survival rate of 74%, which was statistically higher (P=0.0021) than the 44% for the remaining nonresponding patients (pNR). Overall, 43% of the patients with stage T2-T3a disease achieved tumor downstaging (CR, 5%; PR, 38%) compared with 63% of the patients with T3b-T4 (CR, 11%; PR, 52%), although there was no significant difference in 5-year survival curves between the two groups. Conclusions A pathologic complete response was achieved in less than 10% of the cases without a preoperative tumor resection. Unfortunately, most of the responses were only partial. Even though the study appears to suggest a survival advantage for those patients who achieved a downstaging, CMV chemotherapy had a limited curative potential in most of the patients. It seems unlikely that determinant proof will be obtained that neoadjuvant chemotherapy may improve survival over a nontreatment control arm. The intrinsic chemoresistance or the suboptimal response to chemotherapy of bladder cancer remains the most adverse prognostic factor.


Tumori | 1988

Sacral chordoma and rehabilitative treatment of urinary disorders.

Tullio Torelli; Biagio Campo; Giorgio Ordesi; Carlo Pirovano; Alberto Azzarelli; Rita Zanolla

Sacral chordoma is one of the rarest tumors of the central nervous system (less than 1 % of the entire group). Mictional disorders are among the most frequent symptoms and are caused by the extrinsic compression brought to bear on the cauda equina and by surgical demolition of the sacrum. Seven patients who had undergone sacral resection for chordoma, starting from S2, were followed for at least one year. It was observed that mictional disorders were often early symptoms signalling the presence of chordoma. Several patients were affected by a complete bladder denervation (infrasacral lesion) after surgery. Early rehabilitative treatment given after surgery for one year restored normal bladder functions in all the patients whose bladder denervation seemed to be not total (negative Lapides’ test). Even when a complete infrasacral lesion of the bladder has been ascertained, early rehabilitative treatment may well prevent serious renal damage.


International Journal of Gynecology & Obstetrics | 2011

Primary urothelial cell carcinoma of the vagina.

Alessandro Del Gobbo; Carlo Patriarca; Biagio Campo; Paolo Giunta

doi:10.1016/j.ijgo.2011.07.028 A 27-year-old female presented with hallucinations, excessive speech, disorientation, and hyperthermiawithout evidence of infection. Neuroleptic treatment did not improve the clinical picture. Cranial CT was negative. Hyperthermia was complicated by muscular rigidity and seizures that progressed to status epilepticus. The patientwas intubated emergently and admitted to the Intensive Care Unit. Orofacial dyskinesia, catatonic-like behavior, frequent multifocal myoclonus, high blood pressure, tachycardia, diaphoresis, and hypoventilation/desaturation episodes complicated the clinical picture further. The response to 5 different antiepileptic agents was suboptimal. Cranial MRI showed bilateral focal lesions along the frontoparietal subcortical white matter, with no restriction to diffusion. Abdominal CT detected a left adnexal cyst. A paraneoplastic encephalitis was suspected and treated with corticosteroids, immunoglobulins, and plasmapheresis. Anti-NMDA receptor antibodies were positive in cerebrospinal fluid. The cyst was surgically excised. A total intravenous anesthetic including propofol, remifentanil, and rocuronium was used. No complications, unexpected events, or temperature derangement occurred perioperatively and agents such as ketamine, nitrous oxide, and tramadol were avoided. Pathology revealed a mature teratoma. The patients clinical picture improved over the following 2 weeks, but subtle mental changes such as poor communication and retrograde amnesia remained. In a review of 100 cases, the median age of patients with antiNMDA receptor encephalitis was 23 years [6]. These patients initially showed psychiatric symptoms or memory derangements; 76% had seizures, 88% had decreased consciousness, 86% had dyskinesia, 69% had autonomic instability, and 66% suffered hypoventilation. Of the cases, 60% had tumors—most frequently ovarian teratoma, but also mediastinal teratoma. Patients who received early immunotherapy and surgical treatment had better outcome and fewer neurological relapses. Seventy-five patients recovered or had mild deficits, whereas 25 had severe deficits or died. In conclusion, a standard anesthetic, either intravenous or inhaled, demonstrated adequate performance for patients with antiNMDA receptor encephalitis. NMDA antagonists such as ketamine, nitrous oxide, xenon, tramadol, and dextropropoxyphene should be judiciously avoided perioperatively because of the uncertainty about the pharmacodynamic response of an abnormal NMDA receptor.


Tumori | 1986

Renal cell carcinoma and transitional cell carcinomas of the pelvis and bladder in a patient affected by chronic renal failure due to abuse of phenacetin

Biagio Campo; Livio Zanitzer; Tullio Torelli; Antonio M. Bacchioni; Carlo Ferrari; Giorgio Ordesi; Roberto M. Macchi

This is a report on a case of 2 concurrent neoplasms of different histology within the same kidney: a renal cell carcinoma and a transitional cell carcinoma of the renal pelvis in a patient affected by chronic renal failure due to abuse of phenacetin. There was also a transitional cell carcinoma of the urinary bladder.

Collaboration


Dive into the Biagio Campo's collaboration.

Top Co-Authors

Avatar

Patrizio Rigatti

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carlo Patriarca

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Angelo Bolognesi

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francesco Montorsi

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Alberto Briganti

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Alessandra Graziottin

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Alessandro Del Gobbo

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

View shared research outputs
Top Co-Authors

Avatar

Andrea Salonia

Vita-Salute San Raffaele University

View shared research outputs
Researchain Logo
Decentralizing Knowledge